Signals, Powered By EquityPandit
The USFDA has provided its approval to Glenmark Pharma for manufacturing and marketing therapeutical equivalent of Endo Pharmaceutical’s Frova tablets that are used to treat migraine headaches in the American market.
The company has said in a BSE filing that “Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (US FDA) for Frovatriptan Succinate Tablets, 2.5 mg.”
It added that the drug is “therapeutical equivalent of Endo Pharmaceutical’s Frova tablets 2.5 mg.”
